Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Dr. Reddy's Labs has become the world's first company to launch a generic version of Amgen's erythropoiesis-stimulating agent Aranesp (darbepoetin alfa). The biosimilar, called Cresp, has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy, Dr. Reddy's announced Aug. 9
You may also be interested in...
India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim
With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.
India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim
With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.
With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim
MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry